• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Elcelyx Therapeutics

edit

Elcelyx Therapeutics is developing ultra-safe products for weight management and obesity-related metabolic disorders based on the science of nutrient sensing. Elcelyx’ first-in-class Gut Sensory Modulators are delivered directly to the gut where they intensify the body’s natural food-driven signals that trigger a sense of fullness and facilitate glucose regulation. The Elcelyx product candidates, Lovidia for weight management and NewMet for Type 2 diabetes, are composed of active dietary and pharmaceutical ingredients that have been safely used by consumers for decades. Lovidia and NewMet represent reduced-risk, near-term blockbuster opportunities in weight management and diabetes with longer-term opportunities in obesity and prediabetes.

Recent Milestones

edit

• 
  Elcelyx Therapeutics received $20M in Series C funding. (2/14/13)
  Posted 2/14/13 at 5:54pm via finsmes.com
• 
  Elcelyx Therapeutics received $4M in Series B funding. (8/13/12)
  Posted 8/13/12 at 9:00pm via prnewswire.com
• 
  Elcelyx Therapeutics added Alain D. Baron as President and CEO.
  Posted 2/15/13 at 4:50am
• 
  Elcelyx Therapeutics added Martin R. Brown as Chief Business Officer.
  Posted 2/15/13 at 4:50am

Videos

Screenshots

edit

Above: Elcelyx Therapeutics
Uploaded: 8/14/12

Sources

1. Elcelyx Therapeutics Extends Series B Financing for Late-Stage Clinical Programs in Weight Loss and Diabetes (m.prnewswire.com) [edit]
2. Elcelyx Therapeutics Closes $20M Series C Financing (finsmes.com) [edit]